GRIFOLS S A/S (GRFS) Lowered to Neutral at JPMorgan Chase & Co.

GRIFOLS S A/S (NASDAQ:GRFS) was downgraded by equities research analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a note issued to investors on Wednesday, The Fly reports.

Other equities research analysts also recently issued reports about the stock. BidaskClub downgraded shares of GRIFOLS S A/S from a “hold” rating to a “sell” rating in a report on Wednesday, February 28th. Morgan Stanley dropped their price objective on shares of GRIFOLS S A/S from $23.00 to $22.00 and set an “underweight” rating on the stock in a report on Thursday, March 1st. HSBC raised shares of GRIFOLS S A/S from a “reduce” rating to a “hold” rating in a report on Wednesday, March 14th. Finally, Zacks Investment Research raised shares of GRIFOLS S A/S from a “hold” rating to a “buy” rating and set a $23.00 price objective on the stock in a report on Thursday, March 22nd. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $22.50.

GRIFOLS S A/S traded down $0.57, hitting $24.11, during trading on Wednesday, according to MarketBeat Ratings. 763,800 shares of the company traded hands, compared to its average volume of 630,823. The firm has a market cap of $16.78 billion, a P/E ratio of 21.92, a PEG ratio of 1.60 and a beta of 1.24. The company has a debt-to-equity ratio of 1.57, a quick ratio of 1.36 and a current ratio of 3.13. GRIFOLS S A/S has a one year low of $19.92 and a one year high of $25.18.

Several institutional investors have recently made changes to their positions in GRFS. Comerica Bank lifted its holdings in shares of GRIFOLS S A/S by 23.4% in the fourth quarter. Comerica Bank now owns 24,821 shares of the biotechnology company’s stock worth $613,000 after buying an additional 4,712 shares in the last quarter. First Trust Advisors LP lifted its holdings in shares of GRIFOLS S A/S by 3.7% in the fourth quarter. First Trust Advisors LP now owns 1,878,401 shares of the biotechnology company’s stock worth $43,053,000 after buying an additional 67,501 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of GRIFOLS S A/S by 4.7% in the fourth quarter. Wells Fargo & Company MN now owns 199,050 shares of the biotechnology company’s stock worth $4,563,000 after buying an additional 8,901 shares in the last quarter. FDx Advisors Inc. lifted its holdings in shares of GRIFOLS S A/S by 5.2% in the fourth quarter. FDx Advisors Inc. now owns 51,725 shares of the biotechnology company’s stock worth $1,186,000 after buying an additional 2,558 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of GRIFOLS S A/S by 4.8% in the fourth quarter. Geode Capital Management LLC now owns 100,339 shares of the biotechnology company’s stock worth $2,299,000 after buying an additional 4,551 shares in the last quarter. 21.64% of the stock is currently owned by hedge funds and other institutional investors.

About GRIFOLS S A/S

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.

The Fly

Analyst Recommendations for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply